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I.  Executive Summary
The hemoglobinopathies are a group of disorders passed down through families (inherited) in which 
there is abnormal production or structure of the hemoglobin molecule. Sickle cell disease (SCD) is one 
such blood disorder caused by the abnormal hemoglobin that damages and deforms red blood cells. 
The abnormal red cells break down, causing anemia, and obstruct blood vessels, leading to recurrent 
episodes of severe pain and multi-organ ischemic damage. SCD affects millions of people throughout 
the world and is particularly common among people whose ancestors come from sub-Saharan Africa, 
regions in the Western Hemisphere (South America, the Caribbean, and Central America); Saudi Arabia; 
India; and Mediterranean countries such as Turkey, Greece and Italy. There is no widely available cure 
for SCD although some children have been successfully treated with blood stem cell, or bone marrow, 
transplants.1 However, hematopoietic stem cell transplant is not widely done for SCD, because of the 
difficulty in finding a matched donor. Therefore, the number of people with SCD who get transplants is 
low. In addition, there are several complications associated with the procedure, including death in about 5 
percent of people. In SCD, clinical severity varies, ranging from mild and sometimes asymptomatic states 
to severe symptoms requiring hospitalization. Symptomatic treatments exist, and newborn screening 
(NBS) for SCD can reduce the burden of the disease on affected newborns and children. 
Thalassemia is another type of blood disorder that is caused by a defect in the gene that helps 
control the production of the globin chains that make up the hemoglobin molecule.2 There are two 
main types of thalassemia:
• Alpha thalassemia occurs when a gene or genes related to the alpha globin protein are missing 
or changed (mutated). Alpha thalassemias occur most often in persons from Southeast Asia, the 
Middle East, China and in those of African descent.
• Beta thalassemia occurs when a beta globin gene is changed (mutated) so as to affect 
production of the beta globin protein. 
• Beta thalassemias occur most often in persons of Mediterranean origin. To a lesser extent, 
Chinese, other Asians and African Americans can be affected.
In 2013, the National Center on Birth Defects and Developmental Disabilities, Division of Blood 
Disorders (DBD), Centers for Disease Control and Prevention (CDC) in collaboration with the 
Association of Public Health Laboratories (APHL) Newborn Screening and Genetics in Public Health 
Program convened an APHL Hemoglobinopathy Laboratory Workgroup to address issues around 
hemoglobinopathy laboratory testing. The workgroup objectives are as follows: 
• Discuss the issues related to building and enhancing US laboratory capacity in the areas of 
screening and diagnosis of hemoglobinopathies. 
• Conduct an inventory of state and regional labs that are currently performing (or have the capacity 
to develop) sickle cell disease laboratory testing. 
• Develop a training program for implementing laboratory technology in state public health 
laboratories, universities, and community centers for testing. 
• Consult with CDC and other partners to evaluate current laboratory methodologies and make 
recommendations for improvements. 
• Identify and document best practices that have been used in SCD public health laboratory training; 
identify training standards and competency outcomes.
One of the products of the APHL Hemoglobinopathy Laboratory Workgroup is this guidance document on 
hemoglobinopathy laboratory testing and follow-up techniques. This document explores current screening 
and diagnostic methods available that are currently employed by some screening and diagnostic 
laboratories. It also includes an overview of laboratory structure discussing algorithms for testing, 
reporting and follow-up from several programs in the US. Furthermore, this document aims to improve and 
strengthen US and international capabilities by offering best practices thereby contributing to the goal of 
early detection of hemoglobin disorders. 
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III.   Introduction to Hemoglobinopathies
Hemoglobin is a tetramer composed of two α-globin and two non- α -globin chains working in 
conjunction with heme to transport oxygen in the blood.2,3 Normal adult hemoglobin (HbA) is 
designated αA2β
A
2.
2,3 Variant hemoglobin is derived from gene abnormalities affecting the α-globin 
genes (HBA1 or HBA2) or β-globin (HBB) structural genes (exons).2,3,4 More than a thousand 
hemoglobin variants have been identified relative to changes in the globin chains.3 Qualitative 
changes correspond to amino acid substitutions resulting in hemoglobinopathies. Quantitative 
changes like amino acid insertions, deletions or mutations in the intervening sequences (introns) 
correspond to thalassemia and result in decreased globin chain production.2,3,4
Alpha thalassemias are caused by changes (deletions, point mutations, insertions, etc.) in the 
α-globin genes. Production of α-globin is controlled by the four alleles of HBA1 and HBA2. In the 
deletional type α-thalassemias, the number of α-globin gene deletions correlates to disease severity.4 
One α-globin gene deletion is unremarkable (also called silent carrier) whereas a two α-globin gene 
deletion (α-thalassemia trait) and three α-globin gene deletion (HbH disease) have varied clinical and 
hematological features. A four α-globin gene deletion (Hb Bart’s Hydrops fetalis) is severe and not 
typically compatible with life.2,4
Beta globin variants more commonly seen include HbS, HbC, HbD, HbE and HbG. A mutation in one 
β-globin subunit results in a combination of variant and normal hemoglobin and denotes carrier 
or trait status, also known as the heterozygote state. Mutations in both β-globin subunits result 
in disease based on a homozygous or heterozygous expression. In the case of sickle cell anemia 
(HbSS), mutations are homozygous with production of HbS.2 Other diseases classed under sickle 
cell disease (SCD), for example HbSE, HbSC and HbSβ-thalassemia are heterozygous expressions. 
Regardless of an α-globin or β-globin variant, severity of disease can range from insignificant to 
serious or life threatening.2,3,4,5 Therefore, early detection through newborn screening is paramount.6,7
Hemoglobinopathies, specifically HbSS, HbS/β-thalassemia and HbSC disease were added to the 
Recommended Uniform Screening Panel (RUSP) in 2006. The Maternal and Child Health Bureau of 
the Health Resources and Services Administration (HRSA) of the United States (US) in conjunction 
with the American College of Medical Genetics (ACMG) determined these disorders to be clinically 
significant and included them as core targets easily detected by newborn screening. These were 
added based on the severity of illness associated with sickle cell disorders.7 Symptoms range from 
anemia to severe pain and vaso-occlusive crises eventually affecting multiple organ systems with 
chronic deterioration over time.6 Early detection of SCD reduces the risk of invasive Streptococcus 
pneumoniae (pneumococcus) infection through penicillin prophylaxis. In addition, early diagnosis of 
SCD prior to onset of symptoms or complications, allows health workers to educate the family about 
SCD and offer anticipatory guidance, in the context of comprehensive care of the child. Additional 
hemoglobinopathies readily detected by newborn screening were also added as secondary targets.6 
Examples include HbE disease, HbC disease, HbSE disease, etc.
Methods for newborn screening and diagnosis differ across laboratory programs. Some methods 
detect multiple variants whereas others detect only the most common. While some methods 
are automated, others are manual and labor intensive. Diagnostic methods include DNA based 
applications with some procedures requiring sophisticated instrumentation. 
Programs are also structured differently. Some laboratories are screen-only labs whereas others screen 
and perform diagnostic testing. Some use a second tier assay to confirm an abnormal result prior to patient 
referral for diagnosis. In addition, reporting and follow-up algorithms differ between programs. Based on 
these differences a comprehensive review of methodologies and program structures are warranted. 
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IV.   History of Hemoglobinopathy Screening
Prior to 1960s, Sickle cell disease (SCD) was diagnosed mainly through hematological studies and 
clinical manifestations. In the late sixties, only a few states screened some newborns for sickle cell 
disease, among a handful of genetic disorders. In 1971, in response to pressure by African American 
advocacy groups, the US government made sickle cell disease a scientific and health care priority 
by allocating funds for treatment and research. Several Sickle Cell Centers were created in the 
country, mainly associated with universities or medical centers, including some at medical schools 
of Historically Black College and Universities.8 In 1973, a survey of annual workloads of US state 
public health laboratories known as The Consolidated Annual Report (CAR) showed that 12 state 
public health laboratories had some form of sickle cell screening program. (Table 3-5, Consolidated 
Annual Report, 1973).9 On May 16, 1972, under President Nixon, the US Congress signed into law 
the National Sickle Cell Disease – Sickle Cell Anemia Control Act (Public Law 92-294).8 In 1975, the 
first universal newborn screening (NBS) program for SCD was implemented in New York on a pilot 
basis.10 Subsequently, screening was adopted by the remaining states throughout the late 1980s and 
1990s and into the 2000s. Initially, screening was targeted for populations at risk, primarily African 
Americans. However, the missed cases rate was higher than 30% due to difficulty in identifying an 
infant’s race or ethnicity at birth and so universal screening was implemented.11 Later on, other 
hemoglobinopathies were acknowledged as important public health issues.
Since infection from capsulated organisms caused high mortality and morbidity in children with 
SCD, penicillin prophylaxis was introduced in 1986 for infants with SCD.12 Penicillin prophylaxis 
significantly reduced infection-related mortality and became a powerful incentive to implement 
widespread neonatal screening for SCD.12,13,14,15 
Since May 1, 2006, all 50 states and the District of Columbia require and provide universal newborn 
screening (NBS) for SCD and other hemoglobinopathies even though national recommendation 
was made over a quarter of century ago (1987).9,12 NBS is well recognized as the largest and most 
successful health promotion and disease prevention system in the United States. NBS is the practice 
of testing every newborn for certain harmful or potentially fatal conditions that are not otherwise 
apparent at birth. A sample is collected before the newborn leaves the hospital and identifies 
serious, life-threatening conditions before symptoms begin. Although such conditions are usually 
rare, they can affect a newborn’s normal physical and mental development. Early detection is crucial 
in NBS since intervention can prevent death or a lifetime of severe disabilities.
Along with the initial newborn screening goal to identify SCD, other hemoglobin disorders such as, 
beta (β) and alpha (α) thalassemia have gained significant attention in recent years due to the rapidly 
changing demographics in the US as a result of increased immigration. Hence, hemoglobin disorders 
common in other countries are being seen more frequently in the US.16
As it pertains to screening techniques, laboratories originally used citrate agar electrophoresis 
for screening of abnormal hemoglobins in cord blood. The subsequent improvement in the 
hemoglobinopathy electrophoretic techniques, made it possible to screen newborns by using either 
cord blood or heel stick samples (dried blood spots).
Currently, the majority of hemoglobinopathy screening programs use a combination of isoelectric focusing 
(IEF) and high performance liquid chromatography (HPLC) as primary screening methods (Table 1). 
Many programs use second complimentary electrophoretic technique, HPLC, immunologic tests or DNA-
based assays to confirm specimens with abnormal screening results.13 See Table 1 for a distribution of 
laboratories versus methods utilized. Most of the current screening methodologies are sensitive and 
specific in detecting high risk infants; however, each method has its own unique limitations.
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Table 1: Number of Newborn Screening Quality Assurance Program Proficiency Testing 
Participants Using Multi-Level Schemes to Enhance the Specificity of Screening for 
Hemoglobinopathies (2014)
Method
Isoelectric 
Focusing
Bio-
Rad 
HPLC
Extended 
Gradient 
HPLC
Trinity 
Biotech 
(Primus) 
Ultra2 
HPLC
Electrophoresis 
Citrate Agar
Electrophoresis 
Alkaline 
Cellulose 
Monoclonal 
Antibody 
Methods
DNA 
Amplification
Level 1 33 41 2 0 0 0 1 0
Level 2 19 13 5 5 1 1 0 1
Level 3 2 2 1 0 2 0 0 0
Level 4 1 0 0 0 0 0 0 0
Screening programs using any of the screening methods must maintain high-quality results to ensure 
accurate interpretation of the phenotypes for immediate initiation of supportive care for infants 
affected with hemoglobinopathies.
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V. Types of Specimens for Hemoglobinopathy Screening and 
Diagnosis
At one time, programs in the US required cord blood for hemoglobinopathy screening; however 
programs now use dried blood spots (DBS). DBS are collected from a heel prick and spotted onto 
filter paper.17 For additional information on newborn screening specimen collection refer to Clinical 
and Laboratory Standards Institute (CLSI) document NBS01-A6, Blood Collection on Filter Paper for 
Newborn Screening Programs.18 Newborn screening specimens should be properly collected to avoid 
clotting, smearing, inadequately filled circles, oversaturation or scratching by capillary tube. Although 
these specimens may be unsatisfactory for some newborn screening tests, they may be acceptable 
for hemoglobinopathy testing (see NBS01-A6 for details).  
DBS and liquid whole blood are used for screening and/or confirmation of children (greater than one 
year of age) and adults. There are changes in hemoglobin types and quantities through the first year 
of life, but after a year of age the hemoglobin types of an individual are going to remain the same. 
See Figure 1 and Table 2 for changes in relative proportions of globin chains at various stages of 
embryonic, fetal and post-natal life.19 Table 2 lists the percentages of normal and variant hemoglobin 
seen in newborns and older children.
Figure 1: Globin switch during in utero and post-natal life
* Figure courtesy of Deepak Kamat, MD, PhD, FAAP via Healio.com
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Table 2: Normal and Variant Hemoglobin at Birth and in Older Children
For the collection of whole blood samples, Ethylene Diamine Tetra Acetic Acid (EDTA) is the typical anti-
coagulant used. Heparin may interfere with DNA amplification by Polymerase Chain Reaction (PCR). 
For DBS collected from a finger stick, the palmar surface of the finger’s last phalanx is most frequently 
used, see CLSI document GP42-A6 for additional information.20 High heat and humidity can change the 
levels of hemoglobin A and S in DBS samples.21 To maintain the integrity of hemoglobin molecules, high 
humidity and temperature should be minimized during transport and storage.
Blood smears should not be used for hemoglobinopathy screening. A smear is unreliable as it 
requires the presence of sickled cells which may or may not be in circulation at the time of collection. 
Blood smears also cannot differentiate homozygous from heterozygous nor can they detect other 
hemoglobin variants.22
Transfusion may affect hemoglobinopathy screening results. The transfused blood can mask a 
hemoglobinopathy, or the transfused blood may contain a hemoglobin variant that does not belong 
to the patient. In cases of transfusion, hemoglobinopathy screening should be repeated four months 
post transfusion according to the Clinical and Laboratory Standards Institute (CLSI)23 or according to 
individual program guidelines.
There are several different methods as next described that are used for hemoglobinopathy screening 
and confirmation. Specific specimen requirements may vary between these methods. 
* Figure courtesy of Deepak Kamat, MD, PhD, FAAP via Healio.com
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VI.  Methodologies for Hemoglobinopathy Screening and Diagnosis
Various methods for hemoglobinopathy newborn screening and adult testing are employed by 
US laboratories. Many programs traditionally used electrophoresis as the method of choice 
for identification and quantification of aberrant hemoglobins.24 In more recent years, with the 
introduction of universal screening of newborns, technology has emerged that is robust with high 
throughput and greater sensitivity over electrophoresis.24,25 Many of the same methods used for 
screening, such as Isoelectric focusing (IEF) and High performance liquid chromatography (HPLC) 
are also used for diagnosis. Some laboratories employ one or more methods in their protocol for 
detection of hemoglobinopathies. Choice of method depends on the function of the laboratory and 
its testing algorithm. Molecular methods are emerging and are being utilized by some screening 
and diagnostic labs alike to obtain a more comprehensive analysis and determine the nature of the 
hemoglobinopathy and its clinical implications. Below are descriptions of methods used. Descriptions 
include traditional methods requiring a hands-on approach, more current procedures requiring 
automation and lastly, molecular assays. 
Isoelectric focusing (IEF) 
IEF separates proteins in a gel medium that has a pH gradient consisting of ampholytes (zwitterions). 
When a high voltage is applied, narrow buffered zones are created with stable, but slightly different 
pHs (Figure 2). Slower moving proteins migrate through these zones and stop at their individual 
isoelectric points (pI).3 In the case of hemoglobin, these migrate to a zone in the medium where the 
pH of the gel matches the hemoglobin’s pI. At the pI, the charge of the hemoglobin becomes zero 
and ceases to migrate. The hemoglobin migration order of IEF is similar to alkaline electrophoresis.  
Resolution is clear with differentiation of HbC from HbE and HbO and HbS from HbD and HbG 
respectively. HbA and HbF are also clearly differentiated.24 With neonatal specimens, a distinct 
band representing acetylated HbF is readily identified and slightly anodic to HbA.26 Staining may be 
necessary depending on the manufacturer’s recommendations. Gels may be read wet or dry and 
band identification is accomplished by comparison to migration patterns of known quality controls.26 
This method allows for greater precision and accurate quantification than standard electrophoresis. 
It gives excellent resolution in addition to high throughput, but is also labor-intensive and time 
consuming.3,24,26 An alternative method is needed to confirm or differentiate hemoglobin variants 
(bands other than HbF or HbA).26 Fast migrating bands (Hb Bart’s, HbH) can also be identified by IEF.
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High Performance Liquid Chromatography (HPLC)  
Hemoglobins are separated by an analytical cartridge in cation exchange HPLC using a preprogrammed 
buffer gradient with increasing ionic strength to the cartridge (Figure 3). The hemoglobin fractions 
separate based on their ionic interaction with the cartridge.26 The separated fractions pass through a 
flow cell, where absorbance is measured at 415 nm and again at 690 nm to reduce background noise. 
Changes in absorbance are monitored over time producing a chromatogram (absorbance vs. time). 
Each hemoglobin has its own characteristic retention time and is measured from the time of sample 
injection into the HPLC to the maximum point of each peak. Identification of unknown hemoglobin is 
achieved through comparison with known hemoglobin retention times.27 If a peak elutes at a retention 
time not predetermined, it is labeled as an unknown. HPLC achieves good separation and quantitation 
of HbF and HbA2 in addition to screening for variant hemoglobins along with thalassemia. HPLC is highly 
reproducible, offers simplicity with automation, superior resolution and rapid results.27 Some HPLC 
instrument programs can identify hemoglobinopathies from both newborns and adult specimens while 
others identify only one or the other. Identification between adult and newborn specimens depends on 
the algorithm/software/instrument specifications.
Figure 2: Isoelectric Focusing
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The following methods are used less frequently than those described above. Some methods 
have a long history within laboratories and continue to be used to clarify and confirm abnormal 
hemoglobins. Newer technology, like molecular methods, although utilized by few programs, is 
gaining momentum with some programs.
Cellulose Acetate Electrophoresis (Alkaline) 
Cellulose Acetate Electrophoresis or alkaline electrophoresis makes use of the negative charge which 
hemoglobin will adopt under alkaline conditions. Samples are applied to cellulose acetate agar gel 
and hemoglobins are separated by electrophoresis using an alkaline buffer (Tris-EDTA with Boric 
Acid) at pH 8.4.28  Each hemoglobin variant carries a different net charge so it will migrate at varying 
speeds. Following electrophoretic migration, visualization of hemoglobin bands are accomplished 
through staining with Ponceau S, Amino Black and Acid Violet or other similar stains and compared 
with known standards.3,26,28 Hemoglobins are quantified using densitometric scanning and the 
relative percentage of each band is determined.26,28 This method yields rapid and reproducible 
separation of HbA, HbF, HbS and HbC as well as other variant hemoglobins with minimal preparation 
time. However, due to limited sensitivity and because some hemoglobins are electrophoretically 
similar though structurally different, an alternative procedure must be incorporated into the 
screening algorithm for differentiation of these hemoglobins. For example, HbS, HbD, HbG and Hb 
Lepore co-migrate, so they are indistinguishable on alkaline electrophoresis. The same is true for 
HbC, HbA2, HbO-Arab and HbE.
13,24,28 
Figure 3. High-performance Liquid Chromatography
Schematic representation of an HPLC unit. (1) Solvent reservoirs, (2) Solvent degasser, (3) Gradient valve, (4) 
Mixing vessel for delivery of the mobile phase, (5) High-pressure pump, (6) Switching valve in “inject position”, 
(6’) Switching valve in “load position”, (7) Sample injection loop, (8) Pre-column (guard column), (9) Analytical 
column, (10) Detector (i.e. IR, UV), (11) Data acquisition, (12) Waste or fraction collector. “HPLC apparatus” by 
WYassineMrabetTalk. This vector image was created with Inkscape. - Own work. Legend based on : Practical 
High-performance Liquid Chromatography by Veronika Meyer, 4th edition, John Wiley and Sons, 2004, ISBN 
0470093781, p. 7 and chromatography-online.org. Used file: Computer n screen.svg (Crystal SVG icons). Licensed 
under CC BY-SA 3.0 via Wikimedia Commons
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Citrate Agar Electrophoresis (Acid) 
Electrophoresis occurs in an acidic environment at pH 6.2.28 This method is based on the complex 
interactions of the hemoglobin with the electrophoretic buffer and the agar support. Staining allows 
visualization of hemoglobin bands. Acid electrophoresis allows confirmation of variant hemoglobins 
observed in the Cellulose Acetate Electrophoresis procedure and allows good separation of HbC from 
HbE and HbO-Arab.13 It permits additional separation of HbS from HbD and HbG.23,28 Citrate Agar 
electrophoresis appears to be more sensitive than Cellulose acetate for detecting HbF.
Alkaline Globin Chain Electrophoresis
The hemoglobin molecule can be separated into its globin chain components and heme groups 
by the addition of 2-mercaptoethanol and urea. At alkali pH, these globin chains will migrate to 
their characteristic position on a cellulose acetate strip, under an electrical field. The characteristic 
migration pattern aids in the identification of each globin chain type.29
Capillary Zone Electrophoresis 
Charged molecules are separated by their electrophoretic mobility in an alkaline buffer (pH 9.4) 
with separation occurring according to the electrolyte pH and endosmosis or electroosmotic flow.25 
Capillaries function in parallel allowing eight simultaneous analyses. Samples are hemolyzed 
and injected into the anodic end of the capillary. High voltage protein separation is performed 
and hemoglobins migrate from the anodic end of the capillary appearing in specific zones to the 
cathodic end where detection occurs at 415 nm. Results are assessed visually for abnormalities 
with identification of normal and disease patterns. There is improved detection of sickle cell disease 
due to separation of hemoglobin fractions which enables differentiation of HbS from other variants. 
Capillary zone electrophoresis allows clean separation of HbE from HbA2 and facilitates easier 
detection of HbBart’s and HbH.25
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ASSOCIATION OF PUBLIC HEALTH LABORATORIES 14 15Hemoglobinopathies: Current Practices for Screening, Confirmation and Follow-up
Thermic bridge
Temperature
Controlled by 
Peltier device
Anode +Cathode -
Injection < 1nl
Silica Capillary in thermo-
conductive resin (25µm 
diameter)
Migration
Up to 10,000 volts
LED lamp 
Detector
CAPILLARYS Diagram
NET FLOW OF BUFFER IS TOWARDS THE NEGATIVE 
ELECTRODE (CATHODE) 
Diffuse  
layer 
Anode (+) 
Cathode (-) 
Capillary 
wall 
Rigid 
layer 
E 
O 
F 
Figure 6. Net Flow of Buffer towards the Negative Electrode (Cathode)
Figure 5. Capillarys Diagram
ASSOCIATION OF PUBLIC HEALTH LABORATORIES 14 15Hemoglobinopathies: Current Practices for Screening, Confirmation and Follow-up
Molecular Methods
Molecular testing for hemoglobinopathies generally uses three techniques. These are Restriction 
Fragment Length Polymorphism (RFLP), Allelic Discrimination using Real Time PCR end point data 
and DNA Sequencing. DNA extraction of whole blood in the DBS filter paper matrix is needed for all 
PCR-based assays. Methods for DNA extraction include crude boiling preparations, alkaline lysis 
preparations and commercial methods. Each one has its own benefits and limitations, and each 
laboratory needs to determine the best method for their applications.30 
Considerations for all Polymerase Chain Reaction (PCR) based assays
All molecular assays using PCR are susceptible to contamination by aerosolized amplicons. To 
minimize the risk of contamination, at a minimum, assay set-up and amplification/analysis must be 
separated and one-way directional work flow is required.31 Depending upon the volume of specimens 
tested and nature of the work, laboratories may require shoe covers and hair caps in addition to a 
laboratory coat and gloves.
Each PCR run must include a positive control (a genotype positive DBS or genomic DNA i.e., SS, SC, 
AS, AC, etc.) and a negative control, also referred to as a no template control (no DNA control i.e., 
water or reagent only). The positive control verifies that the amplification occurred and the negative 
control will detect contamination of reagents. 
Restriction Fragment Length Polymorphism (RFLP)
RFLP takes advantage of recognition sequences of restriction enzymes that correspond to the 
normal allele or the mutated allele of a gene.32 If the recognition sequence is present, the restriction 
enzyme will restrict (cut) the DNA and the size difference can be visualized by gel electrophoresis 
(Appendix A, Figure 1). 
To use RFLP, DNA is first extracted from DBS and amplified using polymerase chain reaction (PCR). 
The amplified DNA is added to the restriction enzyme reaction and incubated for a prescribed 
amount of time. An aliquot of the mixture is electrophoresed and the size(s) of the fragment(s) is 
visualized after staining, photographed and analyzed. For example, the S mutation in the beta-globin 
B (HBB) gene replaces an adenine with a thymine resulting in an amino acid change from a glutamic 
acid to valine. This change destroys the DdeI restriction enzyme recognition site. After amplifying a 
125bp fragment of the HBB gene, an aliquot of the PCR reaction is added to a mixture containing 
the enzyme DdeI. After a prescribed amount of time, an aliquot of this reaction and a DNA molecular 
weight marker or DNA ladder is electrophoresed on an agarose gel. If the specimen has normal 
hemoglobin (HbAA), the enzyme cuts the DNA into 106bp and 19bp fragments. The 106bp band 
is visible, but the 19bp band is too small to see on the gel. If the only product seen is 125bp, both 
alleles have the S mutation (SS). The specimen would be considered to have both an A and S allele 
(AS) and is classified as a carrier if both the 125 and 106 bp bands are seen (Appendix A, Figure 1).32
The benefits of this method are that it is very easy to perform and analyze and is inexpensive 
compared to the other molecular methods described below. The only instrumentation required is 
a PCR machine, a water bath, an electrophoresis unit and a camera. It is a low throughput method 
because there are a number of manual steps and the amount of time it takes to complete the assay; 
however it is a good choice for laboratories that have a small number of samples to test. A limitation 
of RFLP is that partial restriction (incomplete cutting) of the DNA could result in a homozygous 
specimen being interpreted incorrectly. A positive control of a known genotype is crucial to identify 
this problem. In cases of a double mutation like SC, if the restriction enzymes do not have similar 
activity conditions, two separate reactions are required. 
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Allelic Discrimination using Real-time PCR
Allelic Discrimination (AD) measures fluorescence at the end of PCR to determine if a mutation is 
present. For this technique, a forward and reverse primer spanning the area of interest are used 
as well as hydrolysis probes.32,33 Hydrolysis probes are oligonucleotides that have a fluorophor 
bound to the five prime (5’) end and a quencher molecule bound to the three prime (3’) end. When 
the quencher is in close proximity to the fluorophor, fluorescence cannot be detected. After DNA 
is extracted from the specimen, a PCR reaction with the forward and reverse PCR primers, DNA 
polymerase, nucleotide triphosphates, (dNTPs) and two probes is prepared. One probe corresponds 
to the normal sequence and the other corresponds to the mutant sequence. The fluorophor bound to 
each primer emits fluorescence at different wavelengths and can be distinguished. During PCR, the 
primers and probes bind to their complementary sequences. When DNA polymerase encounters the 
bound probe, the polymerase’s 5’–3’ exonuclease activity degrades it. The fluorescent molecule is 
released, separating it from the quencher and the fluorescence can be measured (Appendix A, Figure 
2). Because amplification occurs exponentially, there is a large increase of fluorophors that are no 
longer in proximity to the quenchers. At the end of the amplification, the fluorescence is measured 
in a real-time PCR machine and the results are analyzed by the software. If the signal from only one 
probe is detected, the sample is homozygous for the sequence complementary to that specific probe. 
If the signals from both probes are detected, then the sample has both a mutant allele and a normal 
allele and is considered a carrier.
This method has a higher throughput than RFLP because the results are generated right after the 
amplification ends, with no further processing. All reactions take place in the PCR tube which never 
has to be opened, thus reducing the risk of contamination. The throughput can be increased by using 
96- or 364-well PCR plates and automation. Limitations include an increased cost for the probes and 
the need for a real-time PCR machine. Although AD is considered a multiplexed assay, the limited 
number of filters in the PCR machines does not allow for a higher order of multiplexing. 
DNA Sequencing
Sanger sequencing is the most comprehensive method of mutation detection and determines the 
exact sequence spanning the area of the primers used. Once DNA is extracted from the sample, it is 
amplified by PCR but in addition to the primers, the DNA polymerase and dNTPs, dideoxynucleotides 
(ddNTPs) are added. Each of the four ddNTPs has a specific fluorophor bound to it, which emits 
a signal at a different wavelength. During amplification, when one of the ddNTPs is incorporated, 
extension stops because the lack of a hydroxyl group does not allow for the addition of the next base. 
The ratio of dNTPs to ddNTPs is optimized to generate fragments that are one base different than the 
next. After amplification, the products are purified, typically by DNA precipitation or by spin column. 
They are loaded onto a capillary electrophoresis instrument that separates the products by size 
based on their charge. When the products move across the path of a laser in the instrument, each 
fluorophor emits a signal at a different wavelength and this information is captured, analyzed by the 
instrument software and the sequence is displayed (Appendix A, Figure 3).34   
The greatest benefit of this method is that every base change in the area of interest is determined 
including single nucleotide polymorphisms, small insertions and small deletions. Sequencing is a 
high-throughput method but all the sequence data must be reviewed by a trained technician, which 
can take a large amount of time depending on the length of sequence and the number of samples. 
For newborn screening laboratories, if sequencing is used for hemoglobinopathy screening, only the 
beta-globin gene, HBB, is usually sequenced because it is relatively small and the most common 
mutations tested are point mutations in HBB. The alpha-globin genes, HBA1 and HBA2, have greater 
than 96% sequence homology making sequencing of these genes more complicated. Many of the 
common alpha-thalassemia mutations are large deletions which cannot be found by sequencing 
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but can be found using gap PCR or Multiplex Ligation-Dependent Probe Amplification. Sequencing 
is the most expensive method compared to RFLP and AD because of the reagents, instrumentation, 
personnel, and review time required for analysis, but it provides the most comprehensive data for the 
beta-globin gene.
Programs use different approaches for hemoglobinopathy screening, confirmation and diagnosis. 
Newborn screening programs however do not routinely screen for the purpose of detecting 
alpha or beta thalassemias although screening methods may detect some forms of these 
hemoglobinopathies. Clinical presentation in conjunction with hematologic features exhibited in the 
complete blood count (CBC) and peripheral blood smear as well as iron studies aid in confirmation 
and diagnosis of thalassemias. Depending on the type of thalassemia diagnosed, family studies may 
be warranted along with genetic counseling.24
To further improve screening and diagnosis of hemoglobinopathies including thalassemias, some 
laboratories are exploring the use of tandem mass spectrometry and whole genome sequencing. 
These methods are promising improved sensitivity and specificity for hemoglobinopathies. However 
as procedures advance, others become less ideal for screening. For example, HbS solubility test, 
although simple and easy to use, is characterized by false positives from other hemoglobin types 
and interfering substances that may be present in the sample. False negatives are commonly seen 
in patients with low hemoglobin or hematocrit levels. Other abnormal hemoglobins are not readily 
detected and result interpretation can be difficult due to the subjectivity of the test.25 Lastly, the HbS 
solubility test cannot differentiate between carrier and disease state for sickle cell disease. Based on 
these limitations, solubility testing is not recommended. 
Additionally, when deciding on which method is most appropriate for hemoglobinopathy detection, it 
is necessary to consider the benefits the method will bring to the individual program. Likewise, it is 
important to consider expense, throughput, ease of use and skills required for implementation and 
routine analysis. Methods also have different limitations that must be evaluated. For example, peak or 
band resolution, differentiation of hemoglobins and result interpretation are important limitations to 
evaluate. The next section explores some of the limitations of the more commonly used applications.
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VII.  Method Advantages, Limitations and Testing Strategy
As of 2015, half of all labs participating in the CDC Newborn Screening Quality Assurance Program’s 
proficiency testing report that they are using IEF as their primary hemoglobinopathy method and the 
other half are using HPLC (Table 1). Both have advantages and limitations, therefore each program 
must examine them to determine which method is best for their lab. The optimal strategy is to 
combine multiple methods to confirm abnormal initial results. The reason for this is what appears to 
be a common trait on one method might actually be different on another. In these circumstances the 
reported result would be Hb variant trait. 
Isoelectric focusing  has the advantage of allowing the reader to view as many as 80 hemoglobin profiles 
per gel. This is very beneficial in high volume laboratories. Variant bands are easily distinguished on a 
gel when compared alongside normal Hb FA profiles and appropriate controls. However, hemoglobin 
bands can leak into neighboring profiles, be poorly focused, distorted or contaminated creating subjective 
interpretations. This can be overcome by having multiple analysts enter results followed by an experienced 
analyst who makes the final call. It is also difficult to quantitate hemoglobin bands when reading IEF 
patterns. Gel preparations are also labor intensive, time consuming, and involve multiple steps. 
Figure 7. Normal Hemoglobin (HbAA) by IEF
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This example clearly illustrates the difference between HbS and HbD. Also note that there is no Hb 
A in the FSS profile. This child either has sickle cell anemia or Sickle beta zero, which will later be 
confirmed by DNA testing.
The image above is a good example of both alpha thalassemia (FAB2) and Hb S trait. FAS is also 
known as S trait due to the fact that it is a heterozygote (only 1 copy of chromosome 11 has the 
mutation for βS). In a homozygous S, there is no A. Homozygous S is also called sickle cell disease 
and the phenotype code is HbSS.
FA
FAB2
FA
FAS
FA
“Here is a good example of a FAB2 and FAS.  FAS is also known as S trait due to 
the fact that it is a heterozygote (only 1 chromosome has the mutation).  In a homozygous S 
there is no Hb A.   Homozygous S is also called sickle cell disease and the phenotype code  
would be FSS. 
Figure 8. Sickle Cell Trait (Hb AS) by IEF
FAD
AD Control
FSS
AFSC Control
FAB1
“This example was chosen because it clearly illustrates the difference between Hb S  
and  D.  Also note that there is no Hb A in the FSS profile.  This child either 
has sickle cell anemia or S beta zero thalassemia which will later be confirmed by  
DNA testing.” 
No Hb A
S
D
Figure 9. Sickle Cell Disease (HbSS) by IEF
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Capillary zone electrophoresis is commonly used in diagnostic laboratories and is an excellent choice 
in situations where few samples need to be run. Due to resolution and sensitivity, however, not all 
hemoglobin variants are detectable by this method. Similar to HPLC, this system also has problems 
with filter paper plugging. 
Figure 10. Sickle Cell Disease (HbSS) by HPLC
An advantage of using HPLC is that it typically includes software that calculates the percent area of 
each hemoglobin peak. This helps with the determination of thalassemias and phenotype reporting. 
Peaks within retention time windows can be identified by software algorithms, which also assists the 
analyst in making the final determination. However, the software determination should not be used to 
assign final phenotype results without examining each chromatogram. HPLC resolution can be low in 
some systems causing variant bands to be overlooked. A known issue with primary HPLC screening is 
system plugging due to filter paper fibers from the blood spot. 
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Less commonly, citrate and cellulose acetate are being used by some laboratories. These methods 
have limited sensitivity and require alternative methods for differentiating abnormal hemoglobins 
sharing the same or similar electrophoretic mobility. Interpretations can be subjective. 
Molecular testing can be added to resolve cases when the newborn has been transfused with 
packed red blood cells. Since the newborn’s phenotype is masked by the donor, DNA testing can be 
used to identify any abnormal hemoglobins. This method is limited by workspace issues required for 
unidirectional flow, training and relatively high cost. Also, it is difficult to obtain proficiency and quality 
control materials which are required for certification through accreditation bodies.
Despite limitations and advantages, programs must consider how to effectively implement testing 
protocols for optimal workflow and efficiency for hemoglobinopathy detection. Specific examples of 
algorithms for hemoglobinopathy detection are provided in the Appendix. All algorithms presented 
despite their corresponding program aid in meeting the goal of early detection and diagnosis of 
hemoglobinopathies.
Figure 11. HPLC Sickle Trait
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VIII. Algorithms for Hemoglobinopathy Detection
NBS programs have varying approaches to screening and reporting. Examples of this are provided in 
the Appendices starting on page 34. However, the goal is the same, to screen for those individuals 
who may be at risk for hemoglobinopathies. The basic screening process entails use of a primary 
method with some labs opting to use a secondary method depending on the type of hemoglobin 
initially detected. Reporting follows based on the result obtained. Methods differ in the ability to 
detect different hemoglobins, so understandably programs will also differ in what is typically reported 
due to method limitations. Additionally, programs may have different distribution of hemoglobins 
reported based on differences in population. To illustrate these variations seen in populations 
nationwide, the top 20 phenotypes reported by a sample of programs are provided in Appendix D.
Unknown Hemoglobin Variants
Invariably, NBS programs will identify unknown hemoglobin variants which may or may not be 
clinically significant. Most hemoglobin variants do not cause serious health problems, with the 
exception of a few. National consensus has yet to be established to guide newborn screening 
programs and clinicians in the follow up of infants with unidentified hemoglobin variants. Final 
identification of unknown variants can be achieved through DNA analysis and consultation with a 
hemoglobin specialist for possible clinical implications. 
Once a variant hemoglobin is identified through screening, it should be confirmed by a secondary or 
alternate method. The American College of Medical Genetics has outlined the algorithm below specifically 
for Hb S screening and confirmation and subsequent actions for confirmed SCD and HbS trait (Figure 12). 
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Figure 12. Newborn Screening Confirmatory Algorithm
Abbreviations/ Key: F, S, A, C, and V = The hemoglobins seen in neonatal screening; HPLC: High 
performance liquid chromatography; IEF: Isoelectric focusing; ‡ = Repeat testing at 6 months age is 
required if genotyping to confirm the newborn screening result is not done.
Source: Adapted from American College of Medical Genetics, 2009 and Dr. Aguinaga-NBS for 
Hemoglobinopathies in TN, from the 11th Annual Research Symposium in Obstetrics and Gynecology 
at Meharry Medical College-Nashville, TN. 2014.
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Figure 13. Basic Hemoglobinopathy Testing Process
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Both IEF and HPLC carry the risk of missing a baby with SCD through misdiagnosis: babies with 
SCD-S/beta-plus thalassemia may be mistakenly reported as having sickle cell trait (FAS). A small 
number of babies inheriting the sickle gene and deletional type hereditary persistence of fetal Hb 
(HPFH) Types 1 or 2, with pancellular distribution of Hb F shows FS on these assays and can be 
misdiagnosed as having sickle cell anemia (FSS). Compound heterozygotes of HbS-deletional type 
HPFH have mild microcytosis and do not have features of sickle cell disease, like the vaso-occlusive 
crises or hemolytic anemia.35  
Regardless of the algorithm employed, a laboratory program must consider and institute quality 
assurance and quality control (QA/QC) activities. Pre-analytic, analytic and post-analytic phases are 
crucial to the proper function of the laboratory system and reporting of quality and accurate results. 
A description of QA/QC protocols are briefly discussed in the following section with information 
provided on the activities of each phase.
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IX.  Quality Assurance for Hemoglobinopathy Screening and Testing
Quality Assurance (QA) is defined as, “a program for the systematic monitoring and evaluation of the 
various aspects of a project, service, or facility to ensure that standards of quality are being met” and 
is often split into three categories, pre-analytic, analytic and post-analytic.36 This section focuses on 
the analytic phase and briefly describes issues in the pre-analytical and post-analytical phases.
Pre-analytical Phase
For newborn screening, this phase includes variables such as specimen collection devices, quality 
of specimen collection and transport to the testing facility. Performance evaluation indicators may 
include the percentage of unsatisfactory specimens (as determined by each program) received and 
the percentage of specimens that are delayed in transport. 
Analytical Phase
This phase includes all factors related to the laboratory testing. A laboratory quality assurance 
program should follow any regulatory guidelines that are applicable. Generally, the laboratory QA 
program has components listed below, at a minimum: 
• A standard operating procedure detailing the testing method, how to interpret results and how to 
resolve problems that may arise
• Flow charts/responsibilities/actions to clarify the role of each person involved in the analysis 
• Quality control (QC) materials to monitor the method over time
• Documentation of any corrective actions taken
• Proficiency Testing (PT) an external quality assessment to monitor the laboratory’s performance 
The most useful QC and PT materials are those in the same matrix as the specimens being 
tested. The materials should include specimens classified as normal as well as those with 
hemoglobinopathies.  Because of the high amount of fetal hemoglobin present in newborn DBS, 
PT for hemoglobinopathy screening requires umbilical cord blood to prepare DBS. Availability of 
umbilical cord blood with hemoglobinopathies is scarce and there are only two programs that 
provide PT, CDC’s Newborn Screening Quality Assurance Program (NSQAP) and the United Kingdom 
National External Quality Assessment (UKNEQAS). If the PT program does not provide specimens 
for the hemoglobinopathies tested, laboratories may follow guidelines published in CLSI document 
GP29-A2.42  No QC materials in the DBS matrix are available for hemoglobinopathy screening.37 
For sickle cell disease and other hemoglobinopathies, NSQAP sends panels of five blind-coded DBS 
PT specimens to participating laboratories three times per year. Participants are asked to test the 
panel and for each specimen, report the method(s) used, the presumptive phenotype, the presumptive 
clinical assessment and any other clinical classifications that are consistent with their program 
operations. An individualized evaluation is provided back to each participant. NSQAP summary reports 
can be publically downloaded at http://www.cdc.gov/labstandards/nsqap_reports.html.
If a participant has an error in a PT survey, NSQAP staff will contact the laboratory to help them 
understand how the error occurred so that measures can be put in place to reduce the risk of the 
error happening again. Due to the limited amount of specimens available, there is currently a waiting 
list to join this program.
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The UKNEQAS provides a PT program for sickle cell and other abnormal hemoglobinopathies in 
DBS. It provides three specimens each month. Further information the web address is http://www.
ukneqas.org.uk. 
Post-analytical Phase
The post-analytical phase includes the transmittal of the screening laboratory results and 
determination of what actions were taken regarding positive screen results.
Newborn screening is an entire system, beginning at the hospital and continuing through to the 
diagnosis of the child. Each part of the newborn screening system is important and needs evaluation 
of any weaknesses. If more information about quality management is necessary there are many 
resources including consensus documents from Clinical Laboratory Standards Institute (www.clsi.
org), World Health Organization’s “Laboratory quality management system: handbook” that can be 
downloaded from their website at http://www.who.int/ihr/publications/lqms/en/ and accreditation 
organizations such as ISO (www.iso.org). 
Communicating positive screen results to a doctor and/or parents and tracking outcomes of 
diagnostic testing are of primary concern. Follow-up processes for newborn screening primarily aim 
to quickly locate an infant with sickle cell disease for diagnosis and treatment. Although protocols 
do vary between programs, the subsequent information focuses specifically on SCD follow-up versus 
non-disease reporting and trait reporting. Additionally, varying algorithms from state programs have 
been included for review. 
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X.  Follow-up
The goal of short-term follow-up is to ensure that all who receive a valid screening test, and screen 
positive results, receive a definitive diagnosis in the most expedient manner possible and appropriate 
clinical management if confirmed.38 The sequence of actions that must take place successfully to 
ensure achievement of this goal includes: 
• Access to the newborn within days of birth or to non-newborns when possible;
• Collection of adequate blood and prompt submission to the designated laboratory;
• Performance of screening laboratory test;
• Correct interpretation of screening test results;
• Notification and dissemination of screening results to appropriate personnel required to facilitate 
achievement of the primary goal;
• Referral to primary healthcare provider and/or specialist.
• Initiation of penicillin prophylaxis for SCD or therapies for other hemoglobinopathies
• Diagnostic testing to confirm screening test results; and,
• Establishment of comprehensive care in a Medical Home.
Follow-up for Hemoglobinopathies 
While follow-up of those with presumptive SCD has a clear purpose, the purpose of follow-up of 
those with other hemoglobinopathies is less clear but has the same potential problems. Successful 
implementation of follow-up involves the following:
• Productive relationships between the screening laboratory and follow-up staff,
• Selection and training of staff reporting results to the family, and 
• Processes or algorithms for follow-up.
Relationships between laboratory and follow-up staff
In some NBS programs the screening laboratory reports directly only to staff of the state NBS 
program to which all results are transmitted. In others, the laboratory also reports directly to the 
hospital of birth and to the listed primary healthcare provider for the baby. Since newborn screening 
for SCD is uniformly state-mandated, the state is responsible for implementation and monitoring of 
the screening program, or its contracted follow-up agency. Either entity should be the direct recipient 
and distributor of screening results. Increasingly, follow-up staff and healthcare providers have direct 
electronic access to the laboratory results held by the state. 
By whatever method of communication between laboratory and follow-up staff, two issues are 
important: first, no single screening test can establish with certainty the phenotype of all the 
common types of SCD and related conditions, and second staff at the laboratory and follow-up 
agency must be fully familiar with the nomenclature of Hb phenotypes reported by the lab and their 
clinical significance. 
Selection and training of staff reporting results to the family
Reporting results for affected individuals and reporting about those with non-disease conditions should 
be fundamentally different. Two types of staff, one with a clinical background and the other with or without 
clinical background should be trained to report results. Training should equip both types of staff with basic 
knowledge about SCD and related thalassemia conditions, their variants and their inheritance patterns, 
and the difference between benign carrier states and clinically significant diseases. 
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Staff who are reporting results for affected individuals should be familiar with the clinical course of SCD 
in infants and young children, be able to answer basic questions about SCD or the suspected related 
disease, and be ready to provide reassurance and support for the family. If staff are not familiar with 
children with SCD, their training should include an internship at a Sickle Cell Center where they can 
observe children with SCD in both outpatient and inpatient settings. This will enhance and make more 
realistic the knowledge acquired through instruction, or reading and video learning materials.
The purpose and value of counseling related to a baby with sickle cell trait or other clinically benign 
hemoglobin conditions or to a baby with no abnormal Hb on newborn screening is not always clear. 
Any family whose newborn is tested for any disorder deserves to receive results and have their 
implications explained. This could be done through staff at a primary health care facility or another 
agency contracted by the state. However, several programs imply, by design, that newborn screening 
opens a window for genetic education and counseling of the parents for future reproductive planning. 
Follow-up staff reporting newborn screening results must have some knowledge of the genetics of 
hemoglobin disorders. 
Process or algorithms for follow-up
Affected individuals: Notification of a family about a (presumptive) serious health problem in an 
otherwise healthy appearing newborn is not a trivial task. Ideally, notification should be done in 
person or by live phone call. The initial conversation should be expected to raise anxiety, and cause 
disappointment and sadness at a time of joy; it may also stir anger or denial. The messenger should be 
someone familiar with the clinical course of SCD in infants, young children and adults, and be able to 
answer basic questions about SCD and ready to provide reassurance and support for the family. 
The processes and algorithms for notification and follow-up often place the primary care service as 
the medical home, presuming that staff is able to interpret screening results and take appropriate 
actions when a baby with a positive screen is reported. Reporting individuals with abnormal 
screening results to a dedicated follow-up agency and/or sickle cell treatment center will increase 
the timeliness of appropriate care. 
In the best circumstances, each child with presumptive SCD should be assigned to one case 
manager who handles the baby from screening test results through establishment at the medical 
home and sickle cell treatment center, where available. 
Non-affected individuals: All parents should be informed about the results of newborn screening. 
Informing parents about results of newborn screening that carry no clinical significance should be 
handled with calmness and reassurance. Algorithms for reporting and following up babies with 
HbFA on screening should not classify them as “Normal” or “Within Normal Limits;” they should 
be reported as “No Abnormal Hb Found.”  While FA is the Hb phenotype of most babies with no 
hemoglobin disorder, babies with FA may be found later to have mild to severe beta or alpha 
thalassemia or transfusion-dependent thalassemia.
“Trait Counseling” of parents of heterozygous babies has become an integral part of newborn 
screening programs for hemoglobin disorders. However, an FA baby may be born to parents who 
BOTH have sickle cell trait or, one may have sickle cell trait while the other is a carrier of another 
abnormal hemoglobin or beta thalassemia. Such parents can have a subsequent baby who has SS or 
another type of SCD.
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Follow up activities for adults who screen positive for a hemoglobinopathy trait: It is important to 
screen at risk individuals for hemoglobinopathies, who are at reproductive age and who may not have 
been screened at birth. 
Dissemination of information about the relevance of adult screening and participation in community 
outreach activities, such as community screenings and health fairs is very important for individuals 
who have not been previously tested. 
If an adult individual has a positive diagnosis for a hemoglobinopathy trait, proper follow-up should 
ensure the understanding of the trait condition, with full explanation of the results, education about the 
trait (including any possible complications or rare clinical manifestations), counseling and the offering 
of hemoglobinopathy testing for the partner, if the couple is contemplating having children. Counseling 
should include the probability of the couple having a child with a hemoglobinopathy in each pregnancy. 
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XII. Appendices
Appendix A: Examples of Molecular Methods for Hb Mutation Detection
Figure 1. PCR-RFLP
Gel picture from Yao-Hua Zhang Y-H and McCabe ERB. 1992. RNA analysis from newborn screening 
dried blood specimens. Hum Genet 89:311-314.
35Hemoglobinopathies: Current Practices for Screening, Confirmation and Follow-up
Figure 2. Allelic Discrimination
 
 
 
https://en.wikipedia.org/wiki/TaqMan Accessed May 19, 2014. Use of trade names is for identification only and does 
not imply endorsement by the Centers for Disease Control and Prevention, the Agency for Toxic Substances and Disease 
Registry, the Public Health Service, or the U.S. Department of Health and Human Services.
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By Estevezj (Own work) [CC BY-SA 3.0 (http://creativecommons.org/licenses/by-sa/3.0)], via 
Wikimedia Commons
Figure 3. Sanger Sequencing
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1 Hb S Trait
2 Low Bart's, Alpha Thalassemia *
3 Hb C Trait
4 Other Variant Trait
5 Moderate Bart's, Alpha Thalassemia
6 Hb E Trait
7 Hb D Trait
8 Hb S Disease
9 HB SC Disease
10 Hb G Trait
11 Elevated Bart's, Hb H Disease
12 Hb E Disease
13 HB C Disease
14 S, Beta Thalassemia
15 Hb O-Arab Trait
16 Beta Thalassemia Major
17 Hb S, Other Disease
18 Hb E Trait and H Disease
19 Hb SE Disease
20 C, Beta Thalassemia
* Low level Bart's no longer reported after June 27 2011.
1 fas 10166 50.22%
2 barts 5022 24.81%
3 fac 3018 14.91%
4 fav 903 4.46%
5 fae 362 1.79%
6 fad 248 1.23%
7 Sickle Cell 173 0.85%
8 Sickle C 112 0.55%
9 fagv 70 0.35%
10 S/B+ 32 0.16%
11 fasv 29 0.14%
12 C/B+ 21 0.10%
13 faev 18 0.09%
14 fadv 17 0.08%
15 C 14 0.07%
16 fag 9 0.04%
17 S/B0 8 0.04%
18 facv 8 0.04%
19 Thal Major 7 0.03%
20 E 5 0.02%
total 20242
2 cases each: Baltimore J, D, D/E, S/HPFH
1 case each: Baltimore N, HPFH, Thal Intermedia/HPFH, Thal + C trait, C/Camden, C/Korle Bu, E/B+, O Arab,
S/Baltimore, S/O Arab, Unidentified Variant
fas
barts
fac
fav
fae
fad
Sickle Cell
Sickle C
fagv
S/B+
fasv
C/B+
faev
fadv
C
fag
S/B0
facv
Thal Major
E
Top 20 Hemoglobinopathies in State 2: 2008-2012
Appendix B
Top 20 Hemoglobinopathies in State 1: 2008-2012
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Confirmed Hemoglobinopathy Data from 1999-2009  
C Beta thalassemia FCA
C Disease
FSC
E disease
FS
FSA
SD
Other
10 Years of Confirmed Data for Hemoglobinopathy Disease in State 3: 1999-2009
TOP 20 HEMOGLOBINOPATHIES IN State 4 2008-2012
*Rank Description Phenotype Nomenclature
1 Normal hemoglobin. FA or AF
2 Hb S trait. FAS or AFS
3 Hb E trait. FAE or AFE
4 Moderate Bart's.  2 gene alpha thalassemia. FAA+Bart's or FAB2
5 Hb variant trait. FA+Var or FAV or AFV
6 Hb C trait. FAC or AFC
7 Hb D trait. FAD or AFD
8 Hb constant spring with low to moderate Bart's. FA+CS+Bart’s or FAXB1 or FAXB2
9 Hb E disease.  Homozygous Hb E. FEE or FE
10 Hb E trait with moderate Bart's.  2 gene alpha thalassemia. FAE+Bart’s or FAEB2
11 High Bart's.  Hb H disease.  3 gene alpha thalassemia. FAA+High Bart's or FAB3
12 Hb S disease.  Sickle cell disease.  Homozygous Hb S. FSS or FS
13 Hb S trait with moderate Bart's. FAS+Bart's or FASB2
14 Hb E trait with constant spring.  2 gene alpha thalassemia. FAE+CS+Bart’s
15 Hb sickle C disease. FSC
16 E beta zero thalassemia.  Heterozygous Hb E. FE-
17 Hb E trait plus an uncommon variant. FAE+Var or FAEV
18 Hb SE disease.  Compound heterozygous Hb SE FSE
19 Hb C disease.  Homozygous Hb C. FCC
20 S beta zero thalassemia.  Heterozygous Hb S. FS-
*Ranked data combined Hbs from 2008 to 2012
Top 20 Hemoglobinopathies in State 4: 2008-2012
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Hemoglobinopathy 
Result Forward to PCR (DNA)
F,A N NOTE:  Y (T) indicates that this result is sent for 
F,A,S Y (T) DNA testing only if demographic information
F,A,C Y (T) shows the baby has been transfused.
F,A,D Y (T)
F,A,Other N
F,S Y
F,C Y
F,S,C Y
F,A,E Y (T)
F,E Y
A,F N
A,S,F Y (T)
A,C,F Y (T)
S,C,F Y
S,F Y
C,F Y
E,F Y
A,A N
A,S Y (T)
A,C Y (T)
A,E Y (T)
A,D Y (T)
S,S Y
S,C Y
C,C Y
E,E Y
F,D Y
F Only Detected Y
F,S (A Questionable) Y
F,C (A Questionable) Y
F,E (A Questionable) Y
F,A,S,Other Y (T) NOTE:  Y (T) indicates that this result is sent for 
A,E,F Y (T) DNA testing only if demographic information
A,D,F Y (T) shows the baby has been transfused.
A,Other N
A,F,Other N
A,F,S Y
A,F,C Y
F,Other Y
F,A,Barts N
F,A,S,Barts Y (T)
F,A,C,Barts Y (T)
F,A,E,Barts Y (T)
F,A,D,Barts Y (T)
F,A,O-Arab Y (T)
F,A,elevated Barts N
F,S,Barts Y
F,S,A Y
F,C,A Y
F,S,C,Barts Y
F,A,Other,Barts N
A,F,Other,Barts N
A,F,S,Barts Y
A,F,D Y
A,G N
F,G N
A,G,F N
F,A,G,Barts N
A,F,G N
F,A,C,Other Y (T)
S,A Y
C,A Y
F,A,G N
Appendix C: State 1 DNA Screening Algorithm
ASSOCIATION OF PUBLIC HEALTH LABORATORIES 40
Appendix D: Hemoglobinopathy Screening Algorithm for State 1
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Appendix E: Hemoglobinopathy Screening Algorithm for State 1 – Older 
Children & Adults
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Code Result Statement
1 F,A Normal
02 F,A,S Probable S Trait.  Notify family of test results.
03 F,A,C Probable C Trait.  Notify family of test results.
04 F,A,D Probable D Trait.  Notify family of test results.
05 F,A,Other Probable Unidentified Hb Variant Trait.  Notify family of test results.  Recommend consultation with pediatric hematologist.  
05F F,A,Other Probable Unidentified Hb Variant Trait.  Notify family of test results.  Recommend consultation with pediatric hematologist.  
05M F,A,Other Probable Unidentified Hb Variant Trait.  Notify family of test results.  Recommend consultation with pediatric hematologist.  
05S F,A,Other Probable Unidentified Hb Variant Trait.  Notify family of test results.  Recommend consultation with pediatric hematologist.  
06 F,S Probable SS Disease.  Refer to pediatric hematologist.  DNA report to follow.
07 F,C Probable CC Disease.  Refer to pediatric hematologist.  DNA report to follow.
08 F,S,C Probable SC Disease.  Refer to pediatric hematologist.  DNA report to follow.
09 F,A,E Probable E Trait.  Notify family of test results.
10 F,E Probable EE Disease.  Refer to pediatric hematologist.  DNA report to follow.
11 A,F Probable Normal.  If result is due to transfusion, repeat in one to three months post transfusion.
12 A,S,F Probable S Trait. Notify family of test results.
13 A,C,F Probable C Trait. Notify family of test results.
14 S,C,F Probable SC Disease.  Refer to pediatric hematologist.  DNA report to follow.
15 S,F Probable SS Disease.  Refer to pediatric hematologist.  DNA report to follow.
16 C,F Probable CC Disease.  Refer to pediatric hematologist.  DNA report to follow.
17 E,F Probable EE Disease.  Refer to pediatric hematologist.  DNA report to follow.
18 A,A Probable Normal.  If result is due to transfusion, repeat in one to three months post transfusion.
19 A,S Probable S Trait. Notify family of test results.
20 A,C Probable C Trait. Notify family of test results.
21 A,E Probable E Trait.  Notify family of test results.
22 A,D Probable D Trait.  Notify family of test results.
Appendix F: State 1 Hemoglobinopathy Result Codes
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Code Result Statement
23 S,S Probable SS Disease.  Refer to pediatric hematologist.  DNA report to follow.
24 S,C Probable SC Disease. Refer to pediatric hematologist.  DNA report to follow.
25 C,C Probable CC Disease.  Refer to pediatric hematologist.  DNA report to follow.
26 E,E Probable EE Disease.  Refer to pediatric hematologist.  DNA report to follow.
27 F,D Probable DD Disease.  Refer to pediatric hematologist.  DNA report to follow.
28 F Only Detected Possible Beta Thalassemia Major.  Refer to pediatric hematologist.  DNA report to follow.  
29 F,S (A Questionable) Possible Sickle Cell or Sickle Beta Thalassemia Disease.   Refer to pediatric hematologist.  DNA report to follow.
30 F,C (A Questionable) Possible CC or Hemoglobin C/Beta Thalassemia Disease.  Refer to pediatric hematologist.  DNA report to follow.
31 F,E (A Questionable) Possible EE or Hemoglobin E/Beta Thalassemia Disease.  Refer to pediatric hematologist.  DNA report to follow.
32 F,A,S,Other Probable S Trait and Unidentified Hb Variant. Notify family of test results. Consult with pediatric hematologist.
33 A,E,F Probable E Trait.  Notify family of test results.
34 A,D,F Probable D Trait.   Notify family of test results.
35 A,Other Probable Unidentified Hb Variant Trait.   Notify family of test results. Recommend consultation with pediatric hematologist.
36 A,F,Other Probable Unidentified Hb Variant Trait.   Notify family of test results. Recommend consultation with pediatric hematologist.
36F A,F,Other Probable Unidentified Hb Variant Trait.   Notify family of test results. Recommend consultation with pediatric hematologist.
36M A,F,Other Probable Unidentified Hb Variant Trait.   Notify family of test results. Recommend consultation with pediatric hematologist.
36S A,F,Other Probable Unidentified Hb Variant Trait.   Notify family of test results. Recommend consultation with pediatric hematologist.
37 A,F,S Probable S Trait.  Notify family of test results.  DNA report to follow.
38 A,F,C Probable C Trait.  Notify family of test results.  DNA report to follow.
39 F,Other Probable Unidentified Hb Variant.  Refer to pediatric hematologist.  DNA report to follow.
40 F,A,Barts Probable Alpha Thalassemia Trait.  Notify family of test results.
41 F,A,S,Barts Probable S Trait and Alpha Thalassemia Trait.  Notify family of test results.
42 F,A,C,Barts Probable C Trait and Alpha Thalassemia Trait.  Notify family of test results.
43 F,A,E,Barts Probable E Trait and Alpha Thalassemia Trait.  Notify family of test results.
44 F,A,D,Barts Probable D Trait and Alpha Thalassemia Trait.  Notify family of test results.
45 F,A,O-Arab Probable O-Arab Trait.  Notify family of test results.
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Code Result Statement
46 F,A,elevated Barts Probable H Disease.  Refer to a pediatric hematologist.
47 F,S,Barts Probable SS Disease and Alpha Thalassemia Trait.  Refer to pediatric hematologist.  DNA report to follow.
48 F,S,A Probable Sickle Beta Thalassemia Disease.  Refer to pediatric hematologist.  DNA report to follow.
49 F,C,A Probable Hemoglobin C/Beta Thalassemia Disease.  Refer to pediatric hematologist.  DNA report to follow.
50 F,S,C,Barts Probable SC Disease and Alpha Thalassemia Trait.  Refer to pediatric hematologist.  DNA report to follow.
51 F,A,Other,Barts Probable Unidentified Hb Variant Trait and Alpha Thalassemia Trait.  Notify family of test results. Consult with pediatric hematologist.
52 A,F,Other,Barts Probable Unidentified Hb Variant Trait and Alpha Thalassemia Trait.   Notify family of test results. Consult with pediatric hematologist.
53 A,F,S,Barts Probable S Trait and Alpha Thalassemia Trait.  Notify family of test results.  DNA report to follow.
54 A,F,D Probable D Trait.  Notify family of test results.  DNA report to follow.
55 A,G Probable G Trait.  Notify family of test results.
56 F,G Probable GG Disease.  Refer to pediatric hematologist.
57 A,G,F Probable G Trait.  Notify family of test results.
58 F,A,G,Barts Probable G Trait and Alpha Thalassemia Trait.  Notify family of test results.  Consult with pediatric hematologist.
59 A,F,G Probable G Trait.  Notify family of test results.
60 F,A,C,Other Probable C Trait and Unidentified Hb Variant Trait. Consult with pediatric hematologist. Notify family of test results.
62 S,A Probable Sickle Beta Thalassemia Disease. Refer to pediatric hematologist.  DNA report to follow.
63 C,A Probable Hemoglobin C/Beta Thalassemia Disease.  Refer to pediatric hematologist.  DNA report to follow.
64 F,A,G Probable G Trait.  Notify family of test results.
65 F,A,S,G Probable S Trait and G Trait.  Notify family of test results.  Consult with pediatric hematologist.
66 F,A,S,G,Barts Probable S Trait, G Trait, and Alpha Thalassemia Trait.  Notify family of test results.  Consult with pediatric hematologist.
67 F,A,C,G Probable C Trait and G Trait.  Notify family of test results.  Consult with pediatric hematologist.
68 F,A,C,G,Barts Probable C Trait, G Trait, and Alpha Thalassemia Trait.   Notify family of test results.  Consult with pediatric hematologist.
69 F,E,Barts Probable EE Disease and Alpha Thalassemia Trait.  Refer to pediatric hematologist.  DNA report to follow.
70 F,C,Barts Probable CC Disease and Alpha Thalassemia Trait.  Refer to pediatric hematologist.  DNA report to follow.
71 F,S,D Probable SD Disease.  Refer to pediatric hematologist.  DNA report to follow.
72 F,C,E Probable CE Disease.  Refer to pediatric hematologist.  DNA report to follow.
73 F,S,E Probable SE Disease.  Refer to pediatric hematologist.  DNA report to follow.
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Code Result Statement
96 Abnormal Refer to mailer for free text result.(Case Management - No)  (PCR - Yes)
97 Abnormal Refer to mailer for free text result.(Case Management - No)  (PCR - No)
98 Abnormal Refer to mailer for free text result.(Case Management - Yes)  (PCR - No)
99 Abnormal Refer to mailer for free text result.(Case Management - Yes)  (PCR - Yes)
100 Abnormal Refer to mailer for free text result. (S trait notification - Yes) (PCR - No)
101 Abnormal Refer to mailer for free text result. (S trait notification - Yes) (PCR - Yes)
BM Retest Bad Measure
LA Retest Light A
NF Retest Not Focused
CT Retest Contaminated
QC Retest Controls Failed
DB Retest Distorted Bands
RN Retest Runs
GQ Retest Gel Quality Not Acceptable
GB Retest Gel Burned
NS Retest No Specimen
LS Retest Light Specimen
SLA RFS Repeat from Screen-Light A
SNF RFS Repeat from Screen - Not Focused
SCT RFS Repeat from Screen - Contaminated
SQC RFS Repeat from Screen - Controls Failed
SDB RFS Repeat from Screen - Distorted Band
SRN RFS Repeat from Screen - Runs
SGQ RFS Repeat from Screen - Gel Quality Not Acceptable
SGB RFS Repeat from Screen - Gel Burned
SLS RFS Repeat from Screen - Light Specimen
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Appendix I: State 4 Hb Screening Algorithm
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Result Code Description (brief)
AA Normal Finding
AA-PB Normal Finding  (previous specimen with moderate Bart's)
AAR Hb A (Age inappropriate, no suitable previous specimen)
AAY Hb A (Age inappropriate, suitable previous specimen)
AC Hb C trait
ACF Hb C trait, Hb F
AD Hb D trait
ADF Hb D trait, Hb F
AE Hb E trait
AEF Hb E trait, Hb F
AEFB2 Hb E trait, moderate Bart's
AEFVB2 Hb A, Hb E, Hb F, Hb variant, moderate Bart's
AEFXB2 Hb E trait, Hb F, Hb constant spring, moderate Bart's
AF Normal Finding
AFB2 Moderate Bart's
AFB3 High Bart's (possible Hb H Disease)
AFC Hb C trait
AFCB2 Hb C trait, moderate Bart's
AFD Hb D trait
AFE Hb E trait
AFEB2 Hb E Trait, Hb F, moderate Bart's
AFEXB2 Hb E trait, Hb F, Hb constant spring, moderate Bart's
AF-PB Normal Finding (previous Hb Bart's)
AFR Hb A, Hb F (age inappropriate,  no suitable previous specimen)
AFS Hb S trait, Hb F
AFSB2 Hb S trait, Hb F, moderate Bart's
AFV Hb variant trait, Hb F
AFVB2 Hb variant trait, Hb F, moderate Bart's
AFXB2 Hb constant spring, Hb F, moderate Bart's
AFXB3 High Bart's, Hb constant spring (possible Hb H Disease)
AFY Hb A, Hb F  (age inappropriate,  suitable previous specimen)
AMBD Ambiguous degradation (suitable previous specimen)
AMBDR Ambiguous degradation (no suitable previous specimen)
AS Hb S trait
ASF Hb S trait, Hb F
ASFB2 Hb S trait, Hb F, moderate Bart's
AV Hb variant trait
AVF Hb variant trait, Hb F
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Result Code Description (brief)
AVFB2 Hb variant trait, Hb F, moderate Bart's
CC Hb C only (possible Hb C disease)
CCF Hb C, Hb F (possible Hb C disease)
CE Hb C, Hb E (possible CE disease)
CEF Hb C, Hb E, Hb F (possible CE disease)
C-F Hb C, Hb F (possible C beta zero thalassemia)
CS Hb C, Hb S (possible sickle C disease)
CSF Hb C, Hb S, Hb F (possible sickle C disease)
E- Hb E only (possible E beta zero thalassemia)
EE Hb E only (possible Hb E disease)
EEF Hb E, Hb F (possible Hb E disease)
FA Normal Finding
FAB2 Moderate Bart's
FAB3 High Bart's (possible Hb H disease)
FAB-PN Moderate Bart's (previous normal specimen)
FAC Hb C trait
FACB2 Hb C trait, moderate Bart's
FACV Hb C trait, Hb variant
FAD Hb D trait
FAE Hb E trait
FAEB2 Hb E trait, moderate Hb Bart's
FAEB3 High Bart's, Hb E trait (possible Hb H disease)
FAEV Hb E trait, Hb variant
FAEXB1 Hb E trait, Hb constant spring, low Bart's
FAEXB2 Hb E trait, Hb constant spring, moderate Bart's
FA-PB Normal Finding - Previous Bart's
FAS Hb S trait
FASB2 Hb S trait, moderate Bart's
FASV Hb S trait, Hb variant
FASVB2 Hb S trait, Hb variant, moderate Bart's
FAV Hb variant trait
FAVB2 Hb variant, moderate Bart's
FAXB1 Hb constant spring, low Bart's
FAXB2 Hb constant spring, moderate Bart's
FAXB3 High Bart's, Hb constant spring (possible Hb H Disease)
FC- Hb C only (possible C beta zero thalassemia)
FC2A Hb C trait (possible C beta plus thalassemia)
FCC Hb C only (possible Hb C disease)
FCE Hb C, Hb E (possible CE disease)
FCS Hb C, Hb S (possible sickle C disease)
FD2A Hb D trait (possible D beta plus thalassemia)
54Hemoglobinopathies: Current Practices for Screening, Confirmation and Follow-up
Result Code Description (brief)
FDD Hb D only (possible Hb D disease)
FE- Hb E only (possible E beta zero thalassemia)
FEA Hb E trait (possible E beta plus thalassemia)
FEE Hb E only (possible Hb E disease)
FEEB2 Hb E only, moderate Bart's
FEEB3 High Bart's, Hb E only (possible Hb H disease and Hb E disease)
FS- Hb F, Hb S (possible S beta zero thalassemia)
FS2A Hb S trait (possible S beta plus thalassemia)
FSC Hb F, Hb S, Hb C (possible sickle C disease)
FSE Hb F, Hb S, Hb E (possible SE disease)
FSS Hb F, Hb S (possible sickle cell disease)
FSSB2 Hb F, Hb S, moderate Bart's (possible sickle cell disease)
FSSB3 Hb F, Hb S, High Bart's (possible sickle cell and Hb H disease)
FSV Hb F, Hb S, Hb variant (possible SV disease)
SC Hb S, Hb C (possible sickle C disease)
SCF Hb S, Hb C, Hb F (possible sickle C disease)
SEF Hb S, Hb E, Hb F (possible SE disease)
SF- Hb S, Hb F (possible S beta zero thalassemia)
SF2A Hb S trait (possible S beta plus thalassemia)
SS Hb S only (possible sickle cell disease)
SSF Hb S, Hb F (possible sickle cell disease)
TO-O Unsuitable, too old for Hb testing (previous suitable specimen)
TO-OR Unsuitable, too old for Hb testing (no previous suitable specimen)
UT Unsuitable transfused (previous suitable specimen)
UT+B Unsuitable transfused, moderate Bart's
UT+C Unsuitable transfused, Hb C trait
UT+E Unsuitable transfused, Hb E trait
UT+S Unsuitable transfused, Hb S trait
UT+VAR Unsuitable transfused, Hb variant trait
UTR Unsuitable transfused (no previous suitable specimen)
XXX No code mapped for this phenotype (custom mailer note)
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